GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nika Pharmaceuticals Inc (OTCPK:NIKA) » Definitions » Buyback Yield %

NIKA (Nika Pharmaceuticals) Buyback Yield % : 0.00 (As of Apr. 25, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Nika Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Nika Pharmaceuticals's current buyback yield was 0.00%.


Nika Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Nika Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nika Pharmaceuticals Buyback Yield % Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial - - - - -

Nika Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nika Pharmaceuticals's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Nika Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nika Pharmaceuticals's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nika Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Nika Pharmaceuticals's Buyback Yield % falls into.


;
;

Nika Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Nika Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 516.6137144
=0.00%

Nika Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 516.6137144
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Nika Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Nika Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nika Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.